Clinical observation of clopidogrel resistance and clinical outcomes on patients with acute coronary syndrome

Abstract

Abstract: AIM: To detect ADP (adenosine diphosphate)-induced platelet aggregation rate of patients with acute coronary syndrome before and after clopidogrel treatment and survey the main cardiovascular events. METHODS: ADP-induced platelet aggregation rates of 88 cases stable angina pectoris patients and 102 cases acute coronary syndrome (ACS) patients were detected before and after 5 days clopidogrel treatment.Patients were divided into three groups:nonresponders, low responders and normal responders according to inhibition degree.The main cardiovascular events were recorded during a month among using simple drug treatment and ACS patients. RESULTS: ADP-induced platelet aggregation rate with ACS patients was much higher than that of patients with stable angina pectoris[(80.4 ±7.8) % vs (56.2 ± 12.1) %, P<0.05] before clopidogrel treatment.Incidence rates of nonresponders and low responders were 21.6 % and 27.4 % respectively during using clopidogrel treatment. CONCLUSION: Patients with ACS have a higher platelet aggregation state.Inhibition levels of platelet aggregation rate have significant inter-individual difference after clopidogrel treatment.Incidence rates of diaphragmatic angina in nonresponders and low responders were obviously higher than that in normal responders(P<0.05).Incidence rate of angina pectoris using drug-eluting stent implantation was lower than that using simple drug treatment (P<0.05).

Key words: acute coronary syndrome, clopidogrel, platelet aggregation ratio

CLC Number:

R541.4

CHEN Bi-lian, XIE Qin-zhi, LI Qing. Clinical observation of clopidogrel resistance and clinical outcomes on patients with acute coronary syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(3): 328-332.

References

[1] CAPRIE Steering Committee.A randomized, blind, trial of clopidogrel verse aspirin in patients at risk for ischemic events(CAPRIE)[J].Lancet, 1996, 348:1329-1339.
[2] Mehta SR, Yusuf S, Peters RJ, et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study [J].Lancet, 2001, 358(9281):527-533.
[3] Steinhubl SR, Berger PB, Mann JT, et al.Early and sustained dual oral anti-platelet therapy following percutaneous coronary intervention:a randomized controlled trial [J].JAMA, 2002, 288(19):2411-2420.
[4] The CURE Trial Investigators.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation[J].N Engl J Med, 2001, 345:494-502.
[5] Fontana P, Dupont A, Gandrille S, et al.Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects[J]. Circulation, 2003, 108(8):989-995.
[6] Mǜller I, Seyfarth M, Rǜ diger S, et al.Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement[J].Heart, 2001, 85(1):92-93.
[7] Nguyen TA, Diodati JG, Pharand C.Resistance to clopidogrel:a review of the evidence[J].J Am Coll Cardiol, 2005, 45(8):1157-1164.
[8] Savcic M, Hauert J, Bachmann F, et al.Clopidogrel loading dose regimens:kinetic profile of pharmacodynamic response in healthy subjects[J].Semin Thromb Hemost, 1999, 25(Suppl 2):15-19.
[9] Cadroy Y, Bossavy JP, Thalamas C, et al.Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans[J].Circulation, 2000, 101(24):2823-2828.
[10] Moshfegh K, Redondo M, Julmy F, et al.Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction:enhanced inhibitory effects of combination therapy[J].J Am Coll Cardiol, 2000, 36(3):699-705.
[11] Lau WC, Gurbel PA, Watkins PB, et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [J].Circulation, 2004, 109(2):166-171.
[12] Matetzky S, Shenkman B, Guetta V, et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[J].Circulation, 2004, 109(25):3171-3175.
[13] Soffer D, Moussa I, Harjai KJ, et al.Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina[J] ? Catheter Cardiovasc Interv, 2003, 59(1):21-25.
[14] Gurbel PA, Bliden KP, Hiatt BL, et al.Clopidogrel for coronary stenting:response variability, drug resistance, and the effect of pretreatment platelet reactivity[J].Circulation, 2003, 107(23):2908-2913.
[15] Clarke TA, Waskell LA.The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin[J].Drug Metab Dispos, 2003, 31(1):53-59.
[16] Hulot JS, Bura A, Villard E, et al.Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects [J]. Blood, 2006, 108(7):2244-2247.
[17] 韩雅玲, 徐凯, 李毅, 等.150 mg 高维持量氯吡格雷提高急性冠脉综合征患者药物洗脱支架植入术后的长期疗效[J].第三军医大学学报, 2008, 30(5):435-438.